Cognition will present clinical efficacy results and new proteomic findings from this Alzheimer’s study at AAIC. Dr. Galvin’s slide presentation as well as Cognition’s three posters will be available ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference.

In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at significantly higher risk for potential harms, according to two systematic reviews.

This is in contrast to the presentation of cutis laxa, where the skin lacks elasticity, hangs in loose folds, and does not rebound rapidly after extended. [10] ...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced ...

Patients with inflammatory bowel disease (IBD) who develop large vessel vasculitis (LVV) present with distinct clinical characteristics, including earlier onset and more severe vascular involvement, ...

Objective Growing evidence suggests that coeliac disease (CeD) is more common in patients with inflammatory bowel disease (IBD) but diagnostic confusion remains due to overlapping histological and ...

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 ...

Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit ...